Company news

Achieve Life Sciences, Inc. news in 2025

Achieve Life Sciences, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Achieve Life Sciences to Host Meetings During the J.P. Morgan Healthcare Conference Week

December 17, 2025

Achieve Life Sciences Reports Third Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program

November 6, 2025

Achieve Life Sciences Meets Key Milestones Advancing Cytisinicline NDA for Smoking Cessation

November 3, 2025

Achieve Life Sciences to Announce Third Quarter Financial Results and Host Conference Call and Webcast on November 6, 2025

October 29, 2025

Achieve Life Sciences Appoints Erik Atkisson as Chief Legal Officer

October 20, 2025

Achieve Life Sciences Receives FDA Commissioner's National Priority Voucher for Cytisinicline for Treatment of Nicotine Dependence for E-cigarette or Vaping Cessation

October 17, 2025

Achieve Life Sciences Announces Granting of New Hire Inducement Awards

October 2, 2025

Achieve Life Sciences Announces Publication in Thorax of Data Demonstrating Cytisinicline’s Potential Efficacy and Tolerability for Smoking Cessation in Individuals with COPD

September 22, 2025

Achieve Life Sciences Promotes Craig Donnelly to Chief Operations Officer

September 18, 2025

Achieve Life Sciences Names Dr. Mark Rubinstein Interim Chief Medical Officer

September 11, 2025

Achieve Life Sciences Announces FDA Acceptance of Cytisinicline New Drug Application for Treatment of Nicotine Dependence for Smoking Cessation

September 3, 2025

Achieve Life Sciences Announces Participation at Upcoming Investor Conferences

September 2, 2025

Achieve Life Sciences Reports Second Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program

August 7, 2025

Achieve Life Sciences to Participate in the BTIG Virtual Biotechnology Conference

July 29, 2025

Achieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 7, 2025

July 24, 2025

Achieve Life Sciences Announces Closing of Public Offering of Common Stock and Partial Exercise of Underwriters’ Option to Purchase Additional Securities

June 30, 2025

Achieve Life Sciences Announces Pricing of $45.0 Million Underwritten Public Offering

June 26, 2025

Achieve Life Sciences Announces Proposed Underwritten Public Offering

June 26, 2025

Achieve Life Sciences Announces Partnership with Omnicom to Execute Integrated, Data-Driven Launch of the First Potential New Treatment for Nicotine Dependence in Nearly Two Decades

June 26, 2025

Achieve Life Sciences Announces Submission of NDA to FDA for Cytisinicline as a Treatment of Nicotine Dependence for Smoking Cessation

June 26, 2025

Achieve Life Sciences to Present at the Jefferies Global Healthcare Conference

May 28, 2025

Achieve Life Sciences to Present New Data at the 2025 ATS International Conference Demonstrating that Cytisinicline Reduced Cravings and Nicotine Intake

May 20, 2025

Achieve Life Sciences Reports First Quarter 2025 Financial Results and Highlights Updates in Cytisinicline Program

May 13, 2025

Achieve Life Sciences to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 13, 2025

May 6, 2025

Achieve Life Sciences Announces Cytisinicline Phase 3 ORCA-3 Trial Publication on Smoking Cessation in JAMA Internal Medicine

April 21, 2025

Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2024 and Provides Update on the Cytisinicline Development Program

March 11, 2025

Achieve Life Sciences to Present at the Barclays 27th Annual Global Healthcare Conference

March 7, 2025

Achieve Life Sciences to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call and Webcast on March 11, 2025

March 6, 2025

Achieve Life Sciences Announces Positive Outcome of Second Data Safety Monitoring Committee Review for the ORCA-OL Clinical Trial

February 9, 2025

Achieve Life Sciences Appoints Dr. Kristen Slaoui and Nancy Phelan to its Board of Directors

January 9, 2025

Achieve Life Sciences Announces Critical Milestone Successfully Reached in ORCA-OL Cytisinicline Clinical Trial Required for NDA Submission

January 6, 2025

Calls in 2025

Decks in 2025